熱門資訊> 正文
Pliant Therapeutics将裁员约45%
2025-05-02 22:27
- Pliant Therapeutics (NASDAQ:PLRX) said on Friday that it will cut approximately 45% of its current workforce, across all departments, amid the company's recent restructuring measures.
- The company will complete the process of headcount reduction by the end of the second quarter of 2025.
- "The restructuring aims to minimize costs and preserve cash reserves as the Company awaits topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast in patients with idiopathic pulmonary fibrosis," Pliant said in a statement.
- The biopharma company expects topline data from the late-stage trial to be available in the second quarter of 2025.
More on Pliant Therapeutics
- Pliant Therapeutics: An Activist On Deck
- Pliant Therapeutics: Strange Volatility
- Pliant downgraded at Stifel on bexotegrast trial discontinuation
- Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF
- Seeking Alpha’s Quant Rating on Pliant Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
